



INTERIM REPORT

1 | 2007

KEY FIGURES

| € million | | Q1 2006 | Q1 2007 | Change |
|--|--------|---------------|----------------------|--------|
| Sales | | 314.4 | 331.2 | +5.3% |
| Scent & Care | | 170.3 | 181.4 | +6.5% |
| Flavor & Nutrition | | 144.1 | 149.8 | +4.0% |
| EBITDA* | | 61.1 | 73.5 | +20.3% |
| EBITDA margin* | in % | 19.4 | 22.2 | +14.2% |
| EBIT* | | 40.7 | 54.2 | +33.2% |
| Net income for the period | | 16.1 | 29.2 | +81.4% |
| Earnings per share | in € | 0.20 | 0.25 | +25.0% |
| Investments in property, plant and equipment | | 7.9 | 7.8 | -1.3% |
| Employees (year-end) | Number | 4,950 | 4,923 | -0.5% |
| | | Dec. 31, 2006 | Mar. 31, 2007 | |
| Total assets | | 1,803.1 | 1,820.3 | +1.0% |
| Shareholders' equity | | 550.6 | 581.2 | +5.6% |
| Equity ratio | in % | 30.5 | 31.9 | +4.6% |

* Adjusted for integration and restructuring expenses in 2006.

- > **Sales growth: 5.3% (at constant exchange rates: 8.9%)**
- > **EBITDA: € 73.5 million**
- > **Net income for the period: € 29.2 million**
- > **Net debt: € 619.1 million**

Contents

| | |
|---|-----------|
| Highlights | 1 |
| Letter to the Shareholders | 2 |
| Share | 4 |
| Interim Consolidated Management Report | 5 |
| Background | 5 |
| Results of Operations | 5 |
| Performance of the Business Divisions | 7 |
| Financial Position | 8 |
| Balance Sheet | 9 |
| Employees | 9 |
| Risks and Opportunities | 9 |
| Events after Close of Period | 10 |
| Outlook | 10 |
| Interim Financial Statements | 11 |
| Notes | 16 |
| Financial Calendar Disclaimer | 24 |
| Contact Imprint | |

Symrise off to a successful start in fiscal year 2007

Dear Shareholders and Friends of Symrise,

Symrise can look back on a very successful first quarter of 2007, that continued the momentum of the company's performance in the past year. We further accelerated our organic growth in a favorable economic climate and made great progress in implementing our strategic realignment. Through effective cost management, we were also able to translate a significant portion of our sales increase into increased profits. This provides us with a solid foundation for the remaining part of fiscal 2007.

Consolidated revenues grew by 5.3% year on year to € 331.2 million. At constant exchange rates, we actually achieved growth of 8.9%. This means that we grew at almost three times the rate of the overall flavor and fragrances market, which expanded by some 3%. The earnings before interest, taxes, depreciation and amortization (EBITDA) grew some 20%, from € 61.1 to € 73.5 million. As a result, the EBITDA margin rose from 19.4% to 22.2%, placing it with the best in the industry.

As in the past, both divisions contributed to the high rates of growth: The Scent & Care division posted a sales growth of 6.5%, while sales in the Flavor & Nutrition division rose by 4.0%. Growth rates at constant rates are much higher, giving an even better picture of the strength of our operations on the international markets: Scent & Care achieved a 10.4% growth in sales, with Flavor & Nutrition at 7.1%.

Symrise continued to make progress in implementing the corporate strategy in the first quarter of the current fiscal year: Sales to key accounts were up, for example, and a number of newly developed products were successfully brought to market.

In the period under review, we acquired Steng Ingredients Ltd., a manufacturer of herb and spice pastes, stocks, marinades and natural flavorings. The company's products are used primarily in refrigerated instant meals or in food with natural ingredients – so-called “clean label” products. Both types of food are currently very much in fashion. Our acquisition of Steng is in keeping with our strategy of consistently offering consumers not only a pure flavor but also an added value (“AND” philosophy).

Our costs remain under control. The ratio of raw material costs to sales in the first quarter of 2007 is more than one percentage point below last year's figure. Distribution and administration cost ratios are also below the previous year's level. We expect the positive sales and earnings trend to continue throughout the year. We anticipate a growth in sales of 5% to 6% in fiscal year 2007. Such rates of growth are in line with our aim to grow at twice the pace of the market. We expect an EBITDA margin of well above 20% in fiscal year 2007.

Yours,



Gerold Linzbach

CONTINUING TO EXPAND



The Share

After the December 11, 2006 debut of Symrise AG on the Frankfurt Stock Exchange, the share price rose from € 17.25 to € 19.44 at the end of the first quarter of 2007.

On March 19, 2007, the Symrise AG stock was admitted to the Mid-Cap Index (MDAX) of the Deutsche Börse. In this index, which includes a total of 50 companies, we have already taken a mid field position, based on trading volume and market capitalization.

Using the date of the initial public offering as a reference point, Symrise stock had already increased 13% by the end of March 2007. In the same period, the MDAX rose by 12% (from 9,080 to 10,201 points). Our addition to the MDAX is both an incentive and a responsibility, for we are now measuring ourselves against a number of excellent companies. The MDAX listing also provides us with the opportunity of access to new groups of investors.

INVESTOR RELATIONS


Investor Relations worked to achieve a seamless transition from the IPO to the creation of the company's first public annual and quarterly reports, while providing new investors with up-to-date and comprehensive support and information.

The Symrise Executive Board and Investor Relations met with various investors in Q1 2007, during road-shows in Frankfurt, London and Paris. Additional road-shows in Europe and North America are scheduled later in the year.

Analysts expressed strong interest in Symrise AG since the IPO. Currently eight analysts publish studies and commentaries on the company's current performance and issue recommendations. We are confident that we will increase coverage in the course of 2007.

PRICE OF SYMRISE AG STOCK IN COMPARISON TO DAX AND MDAX

Indexed (100 = December 11, 2006)



Interim Consolidated Management Report for the Period of January 1 till March 31, 2007

1. BACKGROUND

Global economic climate and industry trend

The overall economic expansion worldwide in 2006 continued with growth of some 3% in the first quarter of 2007. Diverse regional trends can still be observed, however.

Growth rates in Europe declined somewhat compared to 2006, but were still well over 2% in the developed European industrial nations and nearly 5% in the growth regions of Eastern Europe. Economic growth in the United States for the first quarter of 2007 was disappointing. After a 3.3% increase in 2006, growth slowed markedly in the first quarter of 2007 to 1.5%, falling behind that of Europe.

The growth regions of Asia (without Japan) again showed robust growth at 8.6%. China maintained last year's growth rate of 10.7%, while the Indian economy accelerated its growth to 8.6%. Latin America held last year's rate of 4.3%.

We expect industry growth of 2.5% to 3.0% for the first quarter of 2007, based on the stable, moderately growing global consumer climate and the high proportion of developed countries in the market volume of the flavor and fragrance market.

Overall development of business and economic situation

Symrise had a successful start in the new fiscal year 2007. Growth of sales in the first quarter of 2007 was again well above the industry average. At the same time, it was possible to keep costs stable through diligent cost management. The combined effect of both factors yielded a sharp increase in EBITDA in Q1 2007.

2. RESULTS OF OPERATIONS

Sales growth above industry average

Symrise posted an increase of 5.3% in year on year sales in the first quarter of 2007, from € 314.4 million to € 331.2 million. This actually represents a growth of 8.9% when adjusted for currency fluctuations. Based on this latter figure, Symrise grew at almost three times the rate of the industry. As in 2006, the successful implementation of the Group's strategic realignment was a critical factor here. Sales to key accounts were up, for example, and a number of newly developed products were successfully brought to market.

Symrise achieved strong growth in sales of 7.1% in its core market of Europe, Africa and the Middle East (EAME). Currency rate differences led to a drop in sales revenues in North America, however. Adjusted for these differences, growth in this region was 1.8%. Symrise achieved high rates of growth in emerging countries through the specific focus on growth regions. Sales in South America showed a considerable 12.6% increase, while sales in the Asia-Pacific region also rose sharply by 9.5%.

SALES BY REGION

| € million | Q1 2006 | Q1 2007 |
|----------------------------------|--------------|--------------|
| EAME | 174.8 | 187.6 |
| Asia-Pacific | 58.3 | 64.0 |
| North America (including Mexico) | 62.5 | 58.1 |
| South America | 18.9 | 21.1 |
| Other | 0.0 | 0.3 |
| Total | 314.4 | 331.2 |

Progress in key cost items

In addition to sales growth, improvements in key cost items also helped improve the EBIT. Whereas the costs in fiscal year 2006 were still influenced by significant exceptional items and one-time effects, such factors played no role in the first quarter of 2007. The table below thus shows the unadjusted income statement of Q1 2007, and compares this to the income statement

of Q1 2006, both unadjusted and adjusted for exceptional items.

ABBREVIATED INCOME STATEMENT

| € million | Q1 2006 unadjusted | % | Q1 2006 adjusted | % | Q1 2007 | % |
|--------------------------------|-------------------------|-------------|-----------------------|-------------|---------------|--------------|
| Sales revenues | 314.4 | 100.0 | 314.4 | 100.0 | 331.2 | 100.0 |
| Cost of sales | -180.2 | -57.3 | -179.6 | -57.1 | -184.8 | -55.8 |
| Gross profit | 134.2 | 42.7 | 134.8 | 42.9 | 146.4 | 44.2 |
| Selling and marketing expenses | -55.0 | -17.5 | -54.5 | -17.3 | -52.2 | -15.8 |
| R&D expenses | -19.8 | -6.3 | -19.4 | -6.2 | -20.0 | -6.0 |
| Administrative expenses | -22.2 | -7.1 | -20.2 | -6.5 | -21.0 | -6.3 |
| Other operating income | 0.7 | 0.2 | 0.7 | 0.2 | 1.9 | 0.6 |
| Other operating expenses | -0.7 | -0.2 | -0.7 | -0.2 | -0.9 | -0.3 |
| EBIT | 37.2 | 11.8 | 40.7 | 12.9 | 54.2 | 16.4 |

Topline growth spurred a € 5.2 million rise in the cost of sales in Q1 2007 year on year, from € 179.6 to € 184.8 million. As a percentage of sales, however, cost of sales fell from 57.1% in Q1 2006 to 55.8% in Q1 2007. This improvement resulted primarily from an improved ratio of cost of materials to sales stemming from a growth in sales of higher-margin, less material-intensive products and the introduction of measures designed to increase efficiency.

As a result, gross profit rose 8.6%, from € 134.8 to € 146.4 million, due to both growth and the improved raw material cost ratio. This represents a rise in the gross margin from 42.9% in Q1 2006 to 44.2% in Q1 2007.

Compared to the same period last year, selling and marketing expenses fell 4.2%, or € 2.3 million to € 52.2 million, despite the strong growth in sales. Relative to sales, they fell from 17.3% to 15.8%. The primary reason for this reduction is that increases in efficiency and optimization measures in the distribution structure only began to bear fruit in the latter part of 2006.

Research and development expenses rose in the first quarter of 2007 to € 20 million. As a percentage of sales, however, this only constituted 6.0%, a slight decline of 0.2% year on year.


The adjusted administrative expenses increased slightly from € 20.2 million in Q1 2006 to € 21.0 million in Q1 2007.

TRANSITION FROM EBITDA TO EBIT


| € million | Q1 2006 adjusted | Q1 2007 | Change % |
|---|-----------------------|-------------|-------------|
| EBITDA | 61.1 | 73.5 | 20.3 |
| Depreciations | 20.4 | 19.3 | - |
| EBIT | 40.7 | 54.2 | 33.2 |
| Exceptional items: Integration and restructuring expenses | 3.5 | - | |

The EBITDA in Q1 2007 rose disproportionately by 20.3% over the adjusted EBITDA of Q1 2006, from € 61.1 million to € 73.5 million. There was an accompanying sharp rise in the EBITDA margin, from 19.4% to 22.2%. This very positive development is chiefly attributable to the strong sales growth of € 16.8 million.

SALES BY DIVISION
SCENT & CARE
€ million



SALES BY DIVISION
FLAVOR & NUTRITION
€ million



The adjusted EBIT also improved disproportionately by 33.2%, from € 40.7 million to € 54.2 million.

3. PERFORMANCE OF THE BUSINESS DIVISIONS

Financial results reflect the improved capital structure

The financial result in the Q1 2007 remained at last year's level of € - 10.6 million, however the net interest in Q1 2006 was positively influenced by a € 21.4 million gain due to one-off valuation effects.

Earnings before taxes in the period under review rose by 60.3%, from € 27.2 million to € 43.5 million.

Improvement of effective tax rate

The actual income tax expense remained unchanged compared to the previous year at € 7.8 million, despite a strong increase in profitability. Consequently, the effective rate of taxation was only about 16%. The reason for this development is the increased use of historic tax losses carried forward.

Net income and earnings per share

The net income totaled € 29.2 million in Q1 2007 compared to € 16.1 million in the same period last year. The earnings per share (diluted and basic stock) rose accordingly from € 0.20 to € 0.25.

Scent & Care

In the first quarter of 2007, sales in the Scent & Care division rose 6.5% to € 181.4 million. Calculated at constant exchange rates, this constitutes a rise of 10.4%. All regions contributed to this excellent result.

Sales in the EAME region rose 7.2%, well above the estimated market growth. The region of Asia grew by an excellent 9.5%. Currency adjusted growth was even stronger at 13.8%. This reassures us in our growth strategy for this region.

Disproportionate growth of 18.5% was achieved in South America as well. The currency adjusted growth rate of 25.4% reflects this growth in sales even more clearly. A dip of 1.3% was posted in North America. This can be attributed to the fall of the US-dollar. Based on constant exchange rates, an increase in sales of 7.4% was achieved.

The growth in sales of the Scent & Care division was supported by a revamped product portfolio, and by a growth in volume due to a higher number of "core listings" with key accounts. Development in the area of cosmetic ingredients was especially positive.

EBITDA* BY DIVISION

SCENT & CARE

€ million



The adjusted EBITDA in the Scent & Care division rose sharply from € 28.9 million in Q1 2006 to € 38.5 million in Q1 2007. Scent & Care profited not only from higher sales but from an improved cost structure and a reduced raw material cost ratio to sales in Q1 2007, resulting from a revamped product portfolio. The sharp increase in sales of UV filters over the previous year also had a positive effect on profits. These are time-shifted sales, however, as some customers called down sunscreen products very early in the year as part of their business forecast.

Flavor & Nutrition

In the first quarter of 2007, sales in the Flavor & Nutrition division rose 4.0% to € 149.8 million. At constant exchange rates, this constitutes a rise of 7.1%.

The greatest regional increase in sales was 7.5% in EAME. This rise is due primarily to stronger sales of flavorings for non-alcoholic beverages, beer mixes and savory convenience products. The growth in sales based on constant exchange rates was 8.4%.


Our growth strategy in Asia allowed us to post growth of 10.6% in that region. Adjusted for currency fluctuations, this constitutes growth of 14.9%. This growth was achieved primarily through regional key accounts.

In South America, the positive trend from fiscal year 2006 continued, yielding growth of 4.9%. Here, too, the adjustment for currency fluctuations showed rigorous growth of 12.4%. Growth in this region was also achieved primarily through key accounts.

EBITDA* BY DIVISION

FLAVOR & NUTRITION

€ million



Sales in North America fell by € 3.9 million compared to Q1 2006, attributable primarily to currency effects and the postponement of project launches. When adjusted for currency fluctuations, sales in North America fell by 7.4%. At constant exchange rates, we expect to achieve growth in North America in the coming quarters.

The adjusted EBITDA in the Flavor & Nutrition division rose from € 32.2 million in Q1 2006 to € 35.0 million in 2007.

In the period under review, we acquired a 100% shareholding in Steng Ingredients Ltd. ("Steng"). This acquisition is in line with our strategy of consistently offering consumers not only a pure flavor but an added value. Steng is a UK manufacturer of herb and spice pastes, stocks, marinades and natural flavorings. The company realized sales of € 5.4 million in 2006. Steng's products are used primarily in refrigerated instant meals or in food with natural ingredients – so-called "clean label" products. Both types of food are currently in strong demand.

4. FINANCIAL POSITION

New financing structure lowers ongoing costs

Net debt was at € 619.1 million as of March 31, 2007, compared with € 605.1 million on December 31, 2006. The rise is a result of acquisitions and a seasonal increase in working capital.

The improved capital structure after the initial public offering led to significantly improved interest costs, which together with lower debt led to lower financing costs. There was no need to provide security such as liens for the new facility.

* Adjusted for integration and restructuring expenses in 2006.

Cash flow/liquidity

The operating cash flow of € 28.4 million was up by a strong € 13.8 million over the same period last year. The positive effect stemmed from increased profitability and much lower payments for integration and restructuring measures. The seasonal and growth-based rise in working capital claimed a portion of the extra cash flow that was generated.

The increased outflow of funds from financing, from € 16.8 million in Q1 2006 to € 41.0 million in Q1 2007, is a result of the payment of the warrant liability, payments related to the IPO and the repayment of short-term bank loans and shareholder loans. Interest payments to banks came to € 7.0 million in the period under review compared to € 14.5 million in the same period last year.

After taking currency effects into account, the net outflow of funds in Q1 2007 was € 23.0 million compared to € 18.8 million in the same period last year.

Investments and acquisitions

In the first quarter of 2007, Symrise invested € 11.4 million worldwide (Q1 2006: € 17.4 million) in intangible assets, in property, plant and equipment, and in the acquisition of a 100% shareholding in WWS Ltd. of Great Britain, which in turn has a 100% shareholding in Steng Ingredients Ltd. of Great Britain.

5. BALANCE SHEET

| T€ | Dec. 31, 2006 | % | Mar. 31, 2007 | % |
|---|------------------|------|------------------|-------------|
| Cash and cash equivalents | 65,280 | 3.6 | 42,264 | 2.3 |
| Trade receivables | 211,922 | 11.8 | 245,562 | 13.5 |
| Inventories | 214,526 | 11.9 | 219,820 | 12.1 |
| Intangible assets and property, plant and equipment | 1,191,772 | 66.1 | 1,186,483 | 65.2 |
| Other assets | 119,637 | 6.6 | 126,184 | 6.9 |
| Assets | 1,803,137 | | 1,820,313 | |

| T€ | Dec. 31, 2006 | % | Mar. 31, 2007 | % |
|-------------------------------|------------------|-------------|------------------|-------------|
| Current liabilities | 445,878 | 24.7 | 425,606 | 23.4 |
| Noncurrent borrowings | 492,525 | 27.4 | 491,946 | 27.0 |
| Retirement benefit obligation | 180,464 | 10.0 | 183,534 | 10.1 |
| Deferred tax liabilities | 115,391 | 6.4 | 121,429 | 6.7 |
| Other noncurrent liabilities | 18,238 | 1.0 | 16,616 | 0.9 |
| Liabilities | 1,252,496 | 69.5 | 1,239,131 | 68.1 |
| Equity | 550,641 | 30.5 | 581,182 | 31.9 |
| Equity and liabilities | 1,803,137 | | 1,820,313 | |

The balance sheet total of the Symrise Group is nearly unchanged, but the capital structure has undergone a fundamentally positive change through the initial public offering on December 11, 2006.

The intangible assets and property, plant and equipment – at € 1,186.5 million (December 31, 2006: € 1,191.8 million) – constitute some two thirds of the balance sheet total and are completely matched by long-term borrowings and equity. As in the previous year, the fixed assets consist mainly of the goodwill as a result of acquisitions and mergers (€ 416.2 million vs. € 412.4 million on December 31, 2006) and recipes (€ 354.5 million vs. € 360.8 million on December 31, 2006).

Shareholders' equity grew to € 581.2 million at March 31, 2007, constituting an equity ratio of 31.9% (vs. 30.5% on December 31, 2006).

The working capital, when adjusted for currency and evaluation effects, grew by € 39.7 million for seasonal and growth-related reasons (Q1 2006: € 33.2 million).

6. EMPLOYEES

The number of employees remained stable compared to the same period last year, despite the growth in sales. The Symrise Group had 4,923 employees as of March 31, 2007 (previous year: 4,950).

| Number | Mar. 31, 2006 | Mar. 31, 2007 |
|------------------------------|------------------|------------------|
| Manufacturing and technology | 2,071 | 2,100 |
| Sales and marketing | 1,465 | 1,451 |
| Research and development | 884 | 871 |
| Administration | 423 | 397 |
| Trainees | 107 | 104 |
| Total | 4,950 | 4,923 |

7. RISKS AND OPPORTUNITIES

Currently risks, as defined by § 91 (2) of Germany's Stock Corporation Act (Aktiengesetz), that could threaten the continued existence of the Symrise Group are not identifiable. A detailed outline of risks and opportunities to the company and a description of the risk management system can be found on pages 61–65 of the 2006 Annual Report. The statements contained therein continue to apply without significant change.

8. EVENTS AFTER CLOSE OF REPORTING PERIOD

In April 2007, Symrise entered into a strategic partnership with AnalytiCon Discovery GmbH, based in Potsdam, and BRAIN AG, based in Zwingenberg. This alliance will allow Symrise to access new paths in the development of highly effective cosmetic ingredients and further expand its competency in the field of natural substances for skin and hair care. AnalytiCon Discovery GmbH is a leader in the field of generating and utilizing highly diverse natural product compound

libraries featuring fully elucidated structures. Besides its substantial compound libraries, the company brings its expertise for natural substances into the partnership.

BRAIN AG is a leading company of so-called white biotechnology. As a technological leader, it develops new bioactive natural compounds as well as proprietary enzymes for the pharmaceutical, food and cosmetic industries. Under the strategic collaboration, the company will make its customized screening platforms available to Symrise to identify novel bioactive substances for innovative cosmetics.

9. OUTLOOK

We expect the business environment of Symrise to remain positive. Our outlook assumes global economic growth of about 4% annually until 2008, and industry growth of some 3% annually. Because of our presence in the fast-growing regions and a special focus on high-growth market segments, we are confident of attaining a growth in sales well above the industry growth.

We therefore confirm our forecasts made in the Consolidated Management Report for fiscal year 2006.

For the two-year period 2007–2008, we expect continued sales growth averaging 5–6% annually. Profitability – expressed as EBITDA from sales – should rise from 19.8% in 2006 to well above 20%.

Overall anticipated development

In the context of continued good market growth, we currently assume a further increase in earnings in 2007 and 2008. On the basis of a continued positive business momentum, we are confident to pay out a dividend in 2008 in line with industry payout levels.

Opportunities arise in particular from rates of economic growth that exceed the aforementioned expected rates of growth. Our product portfolio also offers the opportunity to profit from a high demand for our products and solutions in the rapid-growth market segments.

Holzminden, April 23, 2007

Symrise AG
Executive Board

Consolidated Income Statement

| T€ | Notes | Q1 2006 | Q1 2007 |
|---|-------|----------------|------------------|
| Sales | 3 | 314,434 | 331,212 |
| Cost of sales | | - 180,259 | - 184,833 |
| Gross profit | | 134,175 | 146,379 |
| Other operating income | | 741 | 1,909 |
| Selling and marketing expenses | | -55,012 | -52,226 |
| Research and development expenses | | - 19,810 | -20,042 |
| Administration expenses | | -22,209 | -21,004 |
| Other operating expenses | | -680 | -859 |
| Profit/(loss) from operations | 3 | 37,205 | 54,157 |
| Share of associate's profit/(loss) | | 160 | 29 |
| Financial income | | 22,032 | 1,628 |
| Financial expenses | | -32,229 | - 12,265 |
| Net finance costs | 5 | -10,197 | -10,637 |
| Profit/(loss) before tax | | 27,168 | 43,549 |
| Income tax | | - 11,079 | -14,397 |
| Net income/(loss) for the period | | 16,089 | 29,152 |
| Earnings per share | 6 | | |
| diluted in € | | 0.20 | 0.25 |
| basic in € | | 0.20 | 0.25 |

Consolidated Balance Sheet

ASSETS

| T€ | Notes | Dec. 31, 2006 | Mar. 31, 2007 |
|--|-------|------------------|------------------|
| Current assets | | | |
| Cash and cash equivalents | | 65,280 | 42,264 |
| Trade receivables | | 211,922 | 245,562 |
| Inventories | | 214,526 | 219,820 |
| Prepayments, other assets and receivables | | 28,640 | 38,064 |
| Tax assets | | 5,228 | 3,793 |
| | | 525,596 | 549,503 |
| Assets of disposal groups classified as held for sale | | | |
| | 9 | 8,498 | 8,400 |
| | | 534,094 | 557,903 |
| Noncurrent assets | | | |
| Deferred tax assets | | 56,525 | 54,952 |
| Other noncurrent assets and receivables | | 14,054 | 14,260 |
| Investments | | 2,716 | 2,710 |
| Investments in an associate | | 3,976 | 4,005 |
| Intangible assets | 7 | 794,921 | 792,785 |
| Property, plant and equipment | 8 | 396,851 | 393,698 |
| | | 1,269,043 | 1,262,410 |
| Assets | | 1,803,137 | 1,820,313 |

EQUITY AND LIABILITIES

| T€ | Notes | Dec. 31, 2006 | Mar. 31, 2007 |
|-------------------------------------|-------|------------------|------------------|
| LIABILITIES | | | |
| Current liabilities | | | |
| Trade payables | | 67,381 | 73,406 |
| Current borrowings | 11 | 177,976 | 169,518 |
| Other provisions | | 14,673 | 12,476 |
| Provisions for taxation | | 28,785 | 34,857 |
| Other liabilities | 12 | 157,063 | 135,349 |
| | | 445,878 | 425,606 |
| Noncurrent liabilities | | | |
| Noncurrent borrowings | 14 | 492,525 | 491,946 |
| Other liabilities | | 16,937 | 15,508 |
| Other provisions | | 1,301 | 1,108 |
| Retirement benefit obligations | 13 | 180,464 | 183,534 |
| Deferred tax liabilities | | 115,391 | 121,429 |
| | | 806,618 | 813,525 |
| Total liabilities | | 1,252,496 | 1,239,131 |
| EQUITY | | | |
| Share capital | 16 | 118,173 | 118,173 |
| Capital reserve | | 1,119,832 | 1,119,832 |
| Revaluation and fair value reserves | | 2,289 | 2,261 |
| Cumulative translation differences | | -63,277 | -61,860 |
| Accumulated deficit | | -626,376 | -597,224 |
| Total equity | | 550,641 | 581,182 |
| Equity and liabilities | | 1,803,137 | 1,820,313 |

Consolidated Cash Flow Statement

| T€ | Notes | Q1 20006 | Q1 2007 |
|--|--------|----------------|----------------|
| Profit or loss | | 16,089 | 29,152 |
| Income tax expenses | | 11,079 | 14,396 |
| Net interest expense | 5 | 15,989 | 9,434 |
| Amortization, depreciation and impairment losses | | 20,701 | 19,385 |
| Change in inventories | | -653 | -4,936 |
| Change in receivables and other assets from operating activities | | -25,731 | -37,257 |
| Change in payables and other liabilities from operating activities | | -6,844 | 2,454 |
| Change in provisions | | -5,077 | -1,886 |
| (Profit)/loss on disposal of assets | 9 | 47 | 63 |
| Income taxes paid | | -5,415 | -2,646 |
| Adjustment for other noncash items | | -5,531 | 267 |
| Net cash flows from operating activities | | 14,654 | 28,426 |
| Investments in intangible assets | 7 | -849 | -1,316 |
| Investments in property, plant and equipment | 8 | -7,093 | -6,435 |
| Investments in subsidiaries, associates and investments | 10 | -9,578 | -3,746 |
| Disposals | | 829 | 381 |
| Interest received | | 419 | 250 |
| Cash flow from investment activities | | -16,272 | -10,866 |
| IPO related payments | | 0 | -6,871 |
| Repayment of warrant liability | 12 | 0 | -10,717 |
| Change in current and noncurrent financial borrowings | 11, 14 | -413 | -15,502 |
| Transaction fees | | -1,950 | -932 |
| Interest paid | | -14,480 | -6,987 |
| Cash flow from financing activities | | -16,843 | -41,009 |
| Net increase/decrease | | -18,461 | -23,449 |
| Effects of changes in exchange rates | | -298 | 433 |
| Cash and cash equivalents as of January 1 | | 54,345 | 65,280 |
| Cash and cash equivalents as of March 31 | | 35,586 | 42,264 |

Consolidated Statement of Changes in Equity

| T€ | Share capital | Capital reserve | Fair value reserve | Revaluation reserve | Cumulated translation differences | Appropriated retained earnings | Accumulated deficit | Total equity |
|------------------------------------|----------------|------------------|--------------------|---------------------|-----------------------------------|--------------------------------|---------------------|----------------|
| Balance on January 1, 2006 | 1,914 | 600,767 | -6 | 2,320 | -49,249 | 6,515 | -536,528 | 25,733 |
| Investments available for sale | | | | | | | | |
| - Fair value movements, net of tax | | | -25 | | | | | -25 |
| Currency translation differences | | | | | -2,609 | | | -2,609 |
| Consolidated net profit | | | | | | | 16,089 | 16,089 |
| Balance on March 31, 2006 | 1,914 | 600,767 | -31 | 2,320 | -51,858 | 6,515 | -520,439 | 39,188 |
| Balance on January 1, 2007 | 118,173 | 1,119,832 | -31 | 2,320 | -63,277 | 0 | -626,376 | 550,641 |
| Investments available for sale | | | | | | | | |
| - Fair value movements, net of tax | | | -7 | | | | | -7 |
| Change in tax rate in 2007 | | | | -21 | | | | -21 |
| Currency translation differences | | | | | 1,417 | | | 1,417 |
| Consolidated net profit | | | | | | | 29,152 | 29,152 |
| Balance on March 31, 2007 | 118,173 | 1,119,832 | -38 | 2,299 | -61,860 | 0 | -597,224 | 581,182 |

Notes to the Abbreviated Interim Consolidated Financial Statements

1. CORPORATE INFORMATION

The Group mainly produces, markets and sells flavorings, fragrances, aroma chemicals and cosmetic ingredients. The registered office of the Group is Mühlenfeldstrasse 1, 37603 Holzmin-den, Germany (commercial register Hildesheim, HRB 200436).

2. ACCOUNTING POLICIES

Principles for the preparation of interim financial statements

The abbreviated, unaudited interim consolidated report for the period from January 1, to March 31, 2007, was prepared in compliance with IAS 34, Interim Reporting. The interim consolidated report was prepared using the same accounting methods applied to the consolidated financial statements of December 31, 2006. It does not contain all the information required for the consolidated financial statements of a fiscal year.

Consolidation principles

The consolidated financial statements comprise the financial statements of Symrise AG and its subsidiaries as of March 31, 2007. The financial statements of Symrise AG and all the subsidiaries it controls are included in the consolidated financial statements.

The financial statements of the subsidiaries are prepared for the same reporting date as the parent company, using uniform accounting policies. Adjustments are made to bring any dissimilar accounting policies in line. All intercompany balances and transactions, including unrealized profits arising from intragroup transactions, are eliminated in full. Unrealized losses from inter-company transactions are fully eliminated unless costs cannot be recovered in the future.

Subsidiaries are fully consolidated from the date of acquisition – i.e., the date on which control is transferred to the Group – and continue to be consolidated until the date that such control ceases.

Equity investments are recognized using the equity method if Symrise does not hold a controlling interest but is still able to exercise significant influence on the business and financial policies of these investees (“associates”).

The consolidated financial statements have been extended to include two additional companies as of March 31, 2007. See section 10 of the Notes for details.

3. SEGMENT REPORTING

Symrise’s operating activities are broken down into two divisions. The Flavor & Nutrition division develops, manufactures and sells flavorings for beverages, foods and pharmaceuticals. The Scent & Care division develops, manufactures and sells fragrances, scents and cosmetic ingredients.

The Group makes the following disclosures required by IAS 34 for its segment reporting. Please refer to the Interim Consolidated Management Report for information on regional sales distribution.

| Q1 2006 T€ | Scent & Care | Flavor & Nutrition | Both divisions |
|--------------------------------------|-----------------|-----------------------|-------------------|
| Sales | | | |
| External sales | 170,346 | 144,088 | 314,434 |
| Result | | | |
| Operating result | 16,482 | 20,723 | 37,205 |
| Share in profit/loss of an associate | 0 | 160 | 160 |
| Financial result | - | - | 10,197 |
| Earnings before taxes | | | 27,168 |
| <hr/> | | | |
| Q1 2007 T€ | Scent & Care | Flavor & Nutrition | Both divisions |
| Sales | | | |
| External sales | 181,369 | 149,843 | 331,212 |
| Result | | | |
| Operating result | 29,168 | 24,989 | 54,157 |
| Share in profit/loss of an associate | 0 | 29 | 29 |
| Financial result | - | - | -10,637 |
| Earnings before taxes | | | 43,549 |

4. SEASONAL INFLUENCES ON OPERATING ACTIVITY

Operations in both the Flavor & Nutrition and Scent & Care divisions are only slightly subject to seasonal effects. Limited seasonal effects may occur in individual business fields or areas of application.

5. FINANCIAL RESULT

| T€ | Q1 2006 | Q1 2007 |
|--|----------------|----------------|
| Interest income | 12,891 | 1,191 |
| Interest expenses | -29,041 | -10,654 |
| Net interest expense | -16,150 | -9,463 |
| Net foreign currency exchange losses, primarily from third-party and intragroup borrowings | -3,188 | -1,491 |
| Other financial income (derivatives) | 9,141 | 437 |
| Other financial expenses | 0 | -120 |
| Total of other financial earnings/expenses | 5,953 | -1,174 |
| Financial result | -10,197 | -10,637 |

Changes to the repayment schedules and interest margins led to revised estimates regarding the timing and amount of future cash flows in the first quarter of 2006. This adjustment resulted in interest income of € 12.5 million in Q1 2006.

The interest expenses include expenses above the nominal interest rate arising from application of the effective interest method to bank debts. This effect came to € 0.2 million in Q1 2007 (Q1 2006: € 7.5 million).

Other finance income of € 0.4 million (Q1 2006: € 9.1 million) is attributable to the measurement of derivative financial instruments (interest rate swaps) at the higher fair value.

6. EARNINGS PER SHARE

Basic earnings per share are calculated by dividing net profit for the year attributable to ordinary shareholders of the parent company by the weighted average number of ordinary shares floating during the year. Before the change of the legal form into Symrise AG, the capital stock of the former Symrise Holding GmbH was used as a basis to calculate a nominal value of € 1 per share. To improve comparability, the capital increase from revenues approved on October 20, 2006, was included in the calculation of the number of ordinary shares.

No option or conversion rights were issued in the first quarter of 2006/2007; as a result, earnings per share were not diluted. The diluted and basic results are therefore the same.

| € | Q1 2006 | Q1 2007 |
|---|-----------|-----------|
| Earnings per share (diluted) | -0.20 | -0.25 |
| Earnings per share (basic) | -0.20 | -0.25 |
| Weighted average number of ordinary shares (in thousands) | 80,373 | 118,173 |

7. INTANGIBLE ASSETS

In the period under review, € 1.3 million was invested in intangible assets (Q1 2006: € 0.8 million). In addition, there are recipes of € 2.9 million and goodwill of € 4.5 million from the acquisition of Steng Ingredients Ltd. of Suffolk (UK) on February 28, 2007. Please refer to section 10.

8. PROPERTY, PLANT AND EQUIPMENT

In the period under review, € 6.4 million was invested in property, plant and equipment (Q1 2006: € 7.0 million). Additional property, plant and equipment with a value of € 0.5 million were acquired along with Steng Ingredients Ltd., Suffolk (UK).

9. ASSETS OF DISPOSAL GROUPS CLASSIFIED AS HELD FOR SALE

In accordance with IFRS 5, assets of a disposal group of T€ 8,400 (December 31, 2006: T€ 8,498) were classified as held for sale.

The Group sold the vacated buildings in Mexico (including the land) in January 2007 for T€ 543. The sale yielded a carrying profit of T€ 439.

The Symrise S.A. production site in Grasse (France) is still for sale. A buyer has been sought since early 2004. The requirements of IFRS 5 have been met since the fall of 2005.

The Executive Board expects that all assets held for sale in France can be sold by the end of 2007.

10. CORPORATE MERGER

Acquisition of Steng Ingredients Ltd., Suffolk, UK

On February 28, 2007, the Group acquired 100% of voting shares in WWS Ltd., which in turn holds 100% of voting shares in Steng Ingredients Ltd., Suffolk (UK). The fair value of the identifiable assets and liabilities of the two companies on the acquisition date were as follows:

| T€ | Carrying amount | Fair value after tax |
|----------------------------------|-----------------|----------------------|
| Recipes | 0 | 2,900 |
| Goodwill consolidation phase 1 | 2,476 | 2,476 |
| Other assets | 494 | 494 |
| Current assets | 1,346 | 1,346 |
| Total assets | 4,316 | 7,216 |
| Subscribed capital | 1 | 1 |
| Reserves and retained earnings | 244 | 2,274 |
| Equity | 245 | 2,275 |
| Liabilities to banks | 3,367 | 3,367 |
| Deferred tax liabilities | 55 | 925 |
| Other liabilities and provisions | 649 | 649 |
| Liabilities | 4,071 | 4,941 |
| Equity and liabilities | 4,316 | 7,216 |

| T€ | |
|-------------------------------------|--------------|
| Purchase price net of cash acquired | 4,324 |
| Cash acquired | - |
| Purchase price | 4,324 |
| Acquired equity | 2,275 |
| Goodwill consolidation phase 2 | 2,049 |
| Goodwill consolidation phase 1 | 2,476 |
| Acquired goodwill | 4,525 |

Since the date of their initial consolidation on February 28, 2007, WWS Ltd. and Steng Ingredients Ltd. of Suffolk (UK) have contributed T€ 477 to Group sales and T€ 60 to the consolidated income in the month of March.

Recipes were valued using the license price method, based on a licensing rate of 10%. It was also assumed that there is a time limit to the use of the know-how of Steng Ingredients Ltd.

Under the purchase agreement, the equivalent of T€ 2,229 (T GBP 1,503) of the purchase price is due on September 7, 2007; T€ 397 (T GBP 268) is due on March 1, 2008, and T€ 280 (T GBP 189) is due on March 1, 2009.

The distribution channels of Steng Ingredients Ltd. will give Symrise access to both the market for ready-to-use ingredients and the growing market of fast-food restaurant chains. The acquisition also expands Symrise's competence in the field of culinary applications.

11. CURRENT BORROWINGS

The current bank borrowings of € 151.9 million (December 31, 2006: € 168.9 million) are loans that are available to the Group through December 13, 2011 through a revolving credit line of € 300 million (Senior Facility – Term B).

Shareholder loans

The current shareholder loans of € 6.1 million reported on December 31, 2006 were repaid in full on March 29, 2007.

Other financial liabilities

The purchase price without additional costs for the shares of Steng Ingredients, Limited (UK) was the equivalent of T€ 4,000 (T GBP 2,698) on March 1, 2007. The acquisition was financed partially through the issuing of debenture bonds totaling T GBP 1,960. The debt remaining on March 31, 2007 was T€ 2,906, of which T€ 2,626 was allocated to current and T€ 280 to non-current debt. The interest rate is 0.5% under LIBOR.

12. OTHER CURRENT LIABILITIES

This item includes the liabilities from the management participation program (MPP) and warrant agreement.

Through the MPP, a large number of senior managers and some members of the former shareholder committee have been offered a participation program that, in return for cash payment, entitles the participants to a bonus payment. The value of the bonus is based on the average share price of the last 60 trading days before December 11, 2007 (due date). To accommodate share price expectations, the MPP liability has been increased by € 0.5 million in Q1 2007 (Q1 2006: € 0.4 million) to € 47.2 million.

The liability from a warrant agreement of € 10.7 million reported on December 31, 2006, was paid in full on January 19, 2007.

13. PENSION OBLIGATIONS

The pension provisions were calculated on the basis of the previous year's value, plus estimated expenses minus payments made. The estimate used the interest rate of December 31, 2006.

The provisions for pensions and similar liabilities rose in the period under review by € 3.1 million to € 183.5 million. This rise was due primarily to estimated interest expenses of € 2.4 million.

14. NONCURRENT BORROWINGS

As of the reporting date, noncurrent borrowings totaling € 491.9 million (December 31, 2006: € 492.5 million) are reported. These loan obligations are primarily to banks at € 489.6 million (December 31, 2006: € 490.4 million).

15. CONTINGENT LIABILITIES

The Group had the following contingent liabilities on March 31, 2007:

Operating leases

Payment obligations consist of operating leases that may not be terminated prematurely and that primarily involve buildings and vehicles. The aggregate future net lease payments are as follows:

| T€ | Operating lease payments Mar. 31, 2007 | Operating sublease payments receivable Mar. 31, 2007 | Net operating lease payments Mar. 31, 2007 | Net operating lease payments Dec. 31, 2006 |
|------------------------|--|---|--|--|
| In the fiscal year | 6,087 | -173 | 5,914 | 13,239 |
| Due in 1 year | 6,931 | -372 | 6,559 | 5,818 |
| Due in 2 years | 5,341 | -368 | 4,973 | 4,460 |
| Due in 3 years | 3,919 | -130 | 3,789 | 3,190 |
| Due in 4 years | 2,849 | -66 | 2,783 | 2,718 |
| Due in 5 years | 2,270 | -66 | 2,204 | 2,099 |
| Due in 6 or more years | 10,061 | -116 | 9,945 | 8,613 |
| Total | 37,458 | -1,291 | 36,167 | 40,137 |

Issuance and endorsement of bills

The issuance and endorsement of trade and commercial bills account for commitments and contingent liabilities toward third parties of T€ 412 as of March 31, 2007 (December 2006: T€ 167).

Other commitments

As of March 31, 2007, the Group had commitments of T€ 6,736 related to the purchase of property, plant and equipment (December 31, 2006: T€ 4,754). Most of these are for production equipment. Additional commitments of T€ 23,000 (December 31, 2006: T€ 22,729) relate to open purchase contracts for other assets and services.

Effective February 1, 2006, Symrise GmbH & Co. KG entered into a ten-year service agreement with Atos Origin GmbH on the outsourcing of internal information technology. The remuneration to be paid decreases steadily over the term of the agreement from € 12.6 million in 2007 to € 10.1 million in 2015. The total obligation to Atos totals some € 110 million.

On March 30, 2007, Symrise GmbH & Co. KG signed two research and development contracts with terms of three years each and total remuneration costs of € 4.2 million plus a results-based development compensation. These agreements took effect on April 1, 2007. The two contracting partners are AnalytiCon Discovery GmbH (Potsdam) and BRAIN Biotechnology Research and Information Network AG (Zwingenberg).

16. SHARE CAPITAL

The share capital of Symrise AG is T€ 118,173. These are no-par bearer shares of common stock, each with a notional value of € 1.00. There are no outstanding contributions to capital.

Authorized capital

On December 1, 2006, the extraordinary shareholder meeting authorized the Executive Board, with the consent of the Supervisory Board, to increase the company's capital stock by up to € 40 million through one or more issuances of new bearer shares without par value by October 31, 2011. The participating rights of new shares may be determined in deviation from § 60 AktG.

17. RELATED PARTY TRANSACTIONS

Related parties are the various EQT funds that, prior to the IPO on December 11, 2006, had control over the Group, as the other shareholders from the former shareholding pool had agreed through the shareholder agreement to grant the EQT special rights. It is presumed that the EQT funds may continue to exercise considerable influence even after the IPO, since they held 15.93% as of the balance sheet date and the remaining shares are largely in free float.

The Executive Board members, former general managers, members of the Supervisory Board and former shareholder representatives also qualify as related persons.

All loan obligations owed to Mr. Horst-Otto Gerberding on December 31, 2006 (€ 1.3 million) were repaid in the first quarter of 2007. Mr. Horst-Otto Gerberding also received compensation of T€ 128 (Q1 2006: T€ 128) for his former activity as general manager.

As of March 31, 2007, the Executive Board and the participants in the MPP indirectly held 1.03% (December 31, 2006: 1.03%) of the subscribed capital of Symrise AG. The participations were acquired through cash payments as part of the Management Participation Program. Mr. Göran Lundberg, Chairman of the Supervisory Board, is also a participant in this program.

All participants have the possibility, based on the share performance, of receiving a one-time cash payment through the MPP. Please refer to Section 12, "Management Participation Program (MPP)."

The following table summarizes the stock transactions reported to the company under § 15a of Germany's Securities Trading Act (WpHG):

| Name and position | Type of transaction | Title of security | Date, place | Number of shares | Price (€) | Total volume (€) |
|--|---------------------|-----------------------|---|------------------|-----------|------------------|
| Dr. Heiner Gürtler (member of Supervisory Board) | Purchase | Symrise no-par shares | December 11, 2006; Frankfurt Stock Exchange | 11,594 | 17.25 | 199,996.50 |

18. DERIVATIVE FINANCIAL INSTRUMENTS

Financial instruments are reported at their fair value as assets or liabilities.

| T€ | Nominal values | | Fair values | |
|----------------------------|----------------|----------------|---------------|---------------|
| | Dec. 31, 2006 | Mar. 31, 2007 | Dec. 31, 2006 | Mar. 31, 2007 |
| Interest rate swaps | 636,887 | 636,387 | 11,358 | 11,729 |
| Forward-exchange contracts | 20,000 | 15,263 | 591 | 819 |
| Total | 656,887 | 651,650 | 11,949 | 12,548 |

Forward-exchange contracts have terms of less than one year. Interest rate swaps have terms of one to five years.

19. SHAREHOLDINGS IN SYMRISE AG

As of the date this interim report was written, Symrise AG had received the following notifications from company shareholders pursuant to the provisions of Germany's Securities Trading Act (WpHG):

JPMorgan Asset Management Holdings Inc., 270 Park Avenue, New York, USA, and JPMorgan Chase & Co. informed us in accordance with § 21 (1) WpHG that their voting rights exceeded the threshold of 3% on January 23, 2007, and have been at 3.13% since that time. These voting rights have been allocated to JPMorgan in accordance with § 22 (1) Sentence 1 No. 6 WpHG.

Threadneedle Asset Management Limited and Threadneedle Asset Management Holdings Limited, 60 St. Mary Axe, London, England, and Ameriprise Financial Inc., 200 Ameriprise Financial Center, Minneapolis, USA, informed us in accordance with § 21 (1) WpHG that their voting rights fell short of the threshold of 3% on January 23, 2007, and have been at 2.40% since that time. These voting rights have been allocated to the companies in accordance with § 22 (1) Sentence 1 No. 6 WpHG.

Newton Investment Management Limited, Mellon Financial Centre, 160 Queen Victoria Street, London, England, informed us in accordance with § 21 (1) WpHG that its voting rights exceeded the threshold of 5% on January 25, 2007, and have been at 5.58% since that time. The voting rights are allocated to the company in accordance with § 22 (1) Sentence 1 No. 6 WpHG.

Mellon Financial Corporation, Pittsburgh, Pennsylvania, USA, informed us on February 26, 2007, that it is the parent company of MBC Investments Corp., Greenville, Delaware 19807, USA. We were also informed that Neptune LLC Pittsburgh, Pennsylvania 15258, USA, is the parent company of Mellon International Limited, London EC4V 4LA, England, which in turn is the parent company of Newton Management Limited, London EC4V 4LA, England. The latter is in turn the parent company of Newton Investment Management Limited, London EC4V 4LA, England.

In addition, Mellon Financial Corporation, Pittsburgh, Pennsylvania, USA – also operating in the name of MBC Investments Corp., Greenville, Delaware 19807, USA; Neptune LLC, Pittsburgh, Pennsylvania 15258, USA; Mellon International Limited, London EC4V 4LA, England and Newton Investment Management Limited, London EC4V 4LA, England – informed us on February 26, 2007, in accordance with § 21 (1) WpHG that its voting rights in Symrise AG exceeded the threshold of 5% on January 25, 2007, and are now at 5.58%. This represents 6,595,115 voting rights. These voting rights are allocated to the company in accordance with § 22 (1) Sentence 1 No. 6 and § 22 (1) Sentence 2 WpHG.

JPMorgan Chase & Co., New York, USA, informed us on April 11, 2007, in accordance with § 21 (1) WpHG that its voting rights in Symrise AG fell short of the threshold of 3% on April 4, 2007, and is now at 2.97%. This corresponds to 3,512,728 voting rights. These voting rights are allocated to the company in accordance with § 22 (1) Sentence 1 No. 6 and Sentence 2 WpHG.


JPMorgan Asset Management Holdings Inc., New York, USA, informed us on April 12, 2007, in accordance with § 21 (1) WpHG that its voting rights in Symrise AG fell short of the threshold of 3% on April 4, 2007, and is now at 2.97%. This corresponds to 3,512,728 voting rights. These voting rights are allocated to the company in accordance with § 22 (1) Sentence 1 No. 6 and Sentence 2 WpHG.

20. EVENTS AFTER THE BALANCE SHEET DATE

Please refer to the Outlook, to be regarded as an integral component of the Interim Consolidated Management Report, for information on the cooperation with AnalytiCon Discovery GmbH, Potsdam, and BRAIN AG, Zwingenberg.

Holzminden, April 23, 2007


Symrise AG
Executive Board



Dr. Gerold Linzbach



Rainer Grimm



Dr. Heinz-Jürgen Bertram



Achim Daub

Financial Calendar | Disclaimer

May 15, 2007

Annual General Meeting, Frankfurt

August 9, 2007

Interim Report 2nd quarter 2007

November 12, 2007

Interim Report 3rd quarter 2007

Disclaimer

This document contains forward-looking statements, which are based on the current estimates and assumptions by the corporate management of Symrise AG. Forward-looking statements are characterized by the use of words such as expect, intend, plan, predict, assume, believe, estimate, anticipate and similar formulations. Such statements are not to be understood as in any way guaranteeing that those expectations will turn out to be accurate. Future performance and the results actually achieved by Symrise AG and its affiliated companies depend on a number of risks and uncertainties and may therefore differ materially from the forward-looking statements. Many of these factors are outside Symrise's control and cannot be accurately estimated in advance, such as the future economic environment and the actions of competitors and others involved in the marketplace. Symrise neither plans nor undertakes to update any forward-looking statements.

Contact | Imprint

Publisher

Symrise AG
Mühlenfeldstraße 1
37603 Holzminden
Germany
T +49 (0) 55 31-90-0
F +49 (0) 55 31-90-16 49

Concept, design and production

Kirchhoff Consult AG, Hamburg, Germany

Photography

Symrise AG

Printing

Peschke Druck, Munich, Germany

Symrise AG
Mühlenfeldstraße 1
37603 Holzminden
Germany

T +49 (0) 55 31-90-0
F +49 (0) 55 31-90-16 49

ir@symrise.com
www.symrise.com